159 related articles for article (PubMed ID: 37656041)
1. RECIST 1.1 Target Lesion Categorical Response in Metastatic Renal Cell Carcinoma: A Comparison of Conventional versus Volumetric Assessment.
Gong AJ; Ruchalski K; Kim HJ; Douek M; Gutierrez A; Patel M; Sai V; Coy H; Villegas B; Raman S; Goldin J
Radiol Imaging Cancer; 2023 Sep; 5(5):e220166. PubMed ID: 37656041
[TBL] [Abstract][Full Text] [Related]
2. Components of Radiologic Progressive Disease Defined by RECIST 1.1 in Patients with Metastatic Clear Cell Renal Cell Carcinoma.
Coy HJ; Douek ML; Ruchalski K; Kim HJ; Gutierrez A; Patel M; Sai V; Margolis DJA; Kaplan A; Brown M; Goldin J; Raman SS
Radiology; 2019 Jul; 292(1):103-109. PubMed ID: 31084479
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy.
Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M
Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356
[TBL] [Abstract][Full Text] [Related]
4. Towards volumetric thresholds in RECIST 1.1: Therapeutic response assessment in hepatic metastases.
Winter KS; Hofmann FO; Thierfelder KM; Holch JW; Hesse N; Baumann AB; Modest DP; Stintzing S; Heinemann V; Ricke J; Sommer WH; D'Anastasi M
Eur Radiol; 2018 Nov; 28(11):4839-4848. PubMed ID: 29736851
[TBL] [Abstract][Full Text] [Related]
5. Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy.
Hall PE; Shepherd STC; Brown J; Larkin J; Jones R; Ralph C; Hawkins R; Chowdhury S; Boleti E; Bahl A; Fife K; Webb A; Crabb SJ; Geldart T; Hill R; Dunlop J; McLaren D; Ackerman C; Wimalasingham A; Beltran L; Nathan P; Powles T
Eur Urol Focus; 2020 Sep; 6(5):999-1005. PubMed ID: 30738795
[TBL] [Abstract][Full Text] [Related]
6. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
[TBL] [Abstract][Full Text] [Related]
7. CT Evaluation of Lymph Nodes That Merge or Split during the Course of a Clinical Trial: Limitations of RECIST 1.1.
Shafiei A; Bagheri M; Farhadi F; Apolo AB; Biassou NM; Folio LR; Jones EC; Summers RM
Radiol Imaging Cancer; 2021 May; 3(3):e200090. PubMed ID: 33874734
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials.
Feinberg BA; Zettler ME; Klink AJ; Lee CH; Gajra A; Kish JK
JAMA Netw Open; 2021 Feb; 4(2):e2036741. PubMed ID: 33630085
[TBL] [Abstract][Full Text] [Related]
9. 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study.
Krajewski KM; Franchetti Y; Nishino M; Fay AP; Ramaiya N; Van den Abbeele AD; Choueiri TK
Oncologist; 2014 May; 19(5):507-14. PubMed ID: 24755461
[TBL] [Abstract][Full Text] [Related]
10. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
Zeng YY; Xiang ZZ; He T; Liu F; Shao BF; Yan RN; Ma JC; Wang XR; Liu L
Oral Oncol; 2020 Dec; 111():104924. PubMed ID: 32736209
[TBL] [Abstract][Full Text] [Related]
11. Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RCC Response to Antiangiogenic Therapy.
Smith AD; Zhang X; Bryan J; Souza F; Roda M; Sirous R; Zhang H; Vasanji A; Griswold M
Radiology; 2016 Nov; 281(2):484-498. PubMed ID: 27603788
[TBL] [Abstract][Full Text] [Related]
12. Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria.
Gafita A; Rauscher I; Fendler WP; Murthy V; Hui W; Armstrong WR; Herrmann K; Weber WA; Calais J; Eiber M; Weber M; Benz MR
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4271-4281. PubMed ID: 35767071
[TBL] [Abstract][Full Text] [Related]
13. Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria.
Krajewski KM; Nishino M; Franchetti Y; Ramaiya NH; Van den Abbeele AD; Choueiri TK
Cancer; 2014 Mar; 120(5):711-21. PubMed ID: 24264883
[TBL] [Abstract][Full Text] [Related]
14. Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.
Kang HC; Gupta S; Wei W; Lu L; Matrana MR; Tannir NM; Choi H
AJR Am J Roentgenol; 2017 Dec; 209(6):1278-1284. PubMed ID: 29064751
[TBL] [Abstract][Full Text] [Related]
15. Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.
Hittinger M; Staehler M; Schramm N; Ubleis C; Becker C; Reiser M; Berger F
Urol Oncol; 2012 Sep; 30(5):695-703. PubMed ID: 21865061
[TBL] [Abstract][Full Text] [Related]
16. Semi-automatic volumetric measurement of response to chemotherapy in lung cancer patients: How wrong are we using RECIST?
Greenberg V; Lazarev I; Frank Y; Dudnik J; Ariad S; Shelef I
Lung Cancer; 2017 Jun; 108():90-95. PubMed ID: 28625656
[TBL] [Abstract][Full Text] [Related]
17. Tumor growth kinetics versus RECIST to assess response to locoregional therapy in breast cancer liver metastases.
Seyal AR; Parekh K; Velichko YS; Salem R; Yaghmai V
Acad Radiol; 2014 Aug; 21(8):950-7. PubMed ID: 24833565
[TBL] [Abstract][Full Text] [Related]
18. CT Intensity Distribution Curve (Histogram) Analysis of Patients Undergoing Antiangiogenic Therapy for Metastatic Renal Cell Carcinoma.
Boos J; Revah G; Brook OR; Rangaswamy B; Bhatt RS; Brook A; Raptopoulos V
AJR Am J Roentgenol; 2017 Aug; 209(2):W85-W92. PubMed ID: 28570097
[TBL] [Abstract][Full Text] [Related]
19. Comparison of response evaluation criteria in solid tumors with volumetric measurements for estimation of tumor burden in pancreatic adenocarcinoma and hepatocellular carcinoma.
Welsh JL; Bodeker K; Fallon E; Bhatia SK; Buatti JM; Cullen JJ
Am J Surg; 2012 Nov; 204(5):580-5. PubMed ID: 22902100
[TBL] [Abstract][Full Text] [Related]
20. RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Krajewski KM; Nishino M; Ramaiya NH; Choueiri TK
AJR Am J Roentgenol; 2015 Mar; 204(3):W282-8. PubMed ID: 25714313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
